Literature DB >> 16645232

Simultaneous measurements of KL-6 and SP-D in patients undergoing thoracic radiotherapy.

Yosuke Matsuno1, Hiroaki Satoh, Hiroichi Ishikawa, Takahide Kodama, Morio Ohtsuka, Kiyohisa Sekizawa.   

Abstract

PURPOSE: Radiation pneumonitis (RP) is a serious complication in patients undergoing thoracic radiotherapy (TRT). Serum KL-6 and SP-D have been shown to increase in several kinds of interstitial pneumonia. To evaluate their clinical usefulness in detecting RP, we serially measured them in patients receiving TRT.
MATERIALS AND METHODS: Thirty-nine patients, who received TRT for lung cancer between July 1999 and April 2004, were prospectively studied. Serum levels of KL-6 and SP-D were measured using enzyme-linked immunosorbent assays. Patients were followed up until August 2004 or their deaths.
RESULTS: During the period, RP occurred in 19 patients. In five patients with diffuse RP extended outside the radiation field, serum KL-6 levels increased, reaching more than 1,000 U/mL. Serum KL-6 levels at 40 Gy in patients who developed RP were higher than those without it (p = 0.0363, Mann-Whitney U test). In addition, serum KL-6 levels at 40 Gy in patients who developed RP were higher than those of pretreatment (p = 0.0126, Wilcoxon signed rank test). On the other hand, there were no statistical differences between sp-d at 40 Gy and those before TRT (P = 0.1165).
CONCLUSIONS: Increased KL-6 at 40 Gy compared with those before treatment in patients undergoing TRT may be of clinical significance. KL-6 proved to be a useful indicator for estimating RP, while usefulness of SP-D was not confirmed in this study.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16645232     DOI: 10.1385/MO:23:1:75

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  25 in total

1.  Circulating antigen KL-6 and lactate dehydrogenase for monitoring irradiated patients with lung cancer.

Authors:  N Kohno; H Hamada; S Fujioka; K Hiwada; M Yamakido; M Akiyama
Journal:  Chest       Date:  1992-07       Impact factor: 9.410

2.  Serum levels of KL-6 are useful biomarkers for severe radiation pneumonitis.

Authors:  K Goto; T Kodama; I Sekine; R Kakinuma; K Kubota; F Hojo; T Matsumoto; H Ohmatsu; H Ikeda; M Ando; Y Nishiwaki
Journal:  Lung Cancer       Date:  2001-10       Impact factor: 5.705

Review 3.  Pulmonary effects of radiation therapy.

Authors:  N J Gross
Journal:  Ann Intern Med       Date:  1977-01       Impact factor: 25.391

4.  Surfactant release as an early measure of radiation pneumonitis.

Authors:  P Rubin; D W Siemann; D L Shapiro; J N Finkelstein; D P Penney
Journal:  Int J Radiat Oncol Biol Phys       Date:  1983-11       Impact factor: 7.038

Review 5.  Severe radiation injuries of the lung.

Authors:  B Roswit; D C White
Journal:  AJR Am J Roentgenol       Date:  1977-07       Impact factor: 3.959

6.  KL-6 as a novel marker for activities of interstitial pneumonia in connective tissue diseases.

Authors:  S Fukaya; H Oshima; K Kato; Y Komatsu; H Matsumura; K Ishii; H Miyama; T Nagai; I Tanaka; A Mizutani; M Katayama; S Yoshida; K Torikai
Journal:  Rheumatol Int       Date:  2000       Impact factor: 2.631

7.  Evaluation of serum KL-6 levels in patients with pulmonary tuberculosis.

Authors:  Y Inoue; K Nishimura; M Shiode; H Akutsu; H Hamada; S Fujioka; S Fujino; A Yokoyama; N Kohno; K Hiwada
Journal:  Tuber Lung Dis       Date:  1995-06

8.  KL-6, a mucin-like glycoprotein, in bronchoalveolar lavage fluid from patients with interstitial lung disease.

Authors:  N Kohno; Y Awaya; T Oyama; M Yamakido; M Akiyama; Y Inoue; A Yokoyama; H Hamada; S Fujioka; K Hiwada
Journal:  Am Rev Respir Dis       Date:  1993-09

9.  Detection of soluble tumor-associated antigens in sera and effusions using novel monoclonal antibodies, KL-3 and KL-6, against lung adenocarcinoma.

Authors:  N Kohno; M Akiyama; S Kyoizumi; M Hakoda; K Kobuke; M Yamakido
Journal:  Jpn J Clin Oncol       Date:  1988-09       Impact factor: 3.019

10.  Molecular biology mechanisms in the radiation induction of pulmonary injury syndromes: interrelationship between the alveolar macrophage and the septal fibroblast.

Authors:  P Rubin; J Finkelstein; D Shapiro
Journal:  Int J Radiat Oncol Biol Phys       Date:  1992       Impact factor: 7.038

View more
  6 in total

1.  Serum KL-6 levels in lung cancer patients with or without interstitial lung disease.

Authors:  Kunihiko Miyazaki; Koichi Kurishima; Katsunori Kagohashi; Mio Kawaguchi; Hiroichi Ishikawa; Hiroaki Satoh; Nobuyuki Hizawa
Journal:  J Clin Lab Anal       Date:  2010       Impact factor: 2.352

Review 2.  Prediction of radiation pneumonitis in lung cancer patients: a systematic review.

Authors:  Xiao-Jing Zhang; Jian-Guo Sun; Jie Sun; Hua Ming; Xin-Xin Wang; Lei Wu; Zheng-Tang Chen
Journal:  J Cancer Res Clin Oncol       Date:  2012-07-29       Impact factor: 4.553

Review 3.  Biologically conformal treatment: biomarkers and functional imaging in radiation oncology.

Authors:  Yaacov Richard Lawrence; Maria Werner-Wasik; Adam P Dicker
Journal:  Future Oncol       Date:  2008-10       Impact factor: 3.404

4.  Importance of serial changes in biomarkers in idiopathic pulmonary fibrosis.

Authors:  Akihiko Sokai; Kiminobu Tanizawa; Tomohiro Handa; Kumiko Kanatani; Takeshi Kubo; Kohei Ikezoe; Yoshinari Nakatsuka; Shinsaku Tokuda; Toru Oga; Toyohiro Hirai; Sonoko Nagai; Kazuo Chin; Michiaki Mishima
Journal:  ERJ Open Res       Date:  2017-08-30

5.  Measurement of exhaled nitric oxide and serum surfactant protein D levels for monitoring radiation pneumonitis following thoracic radiotherapy.

Authors:  Hideya Yamazaki; Norihiro Aibe; Satoaki Nakamura; Naomi Sasaki; Gen Suzuki; Ken Yoshida; Kei Yamada; Masahiko Koizumi; Taichiro Arimoto; Yoshinobu Iwasaki; Yoshiko Kaneko; Koichi Takayama
Journal:  Oncol Lett       Date:  2017-08-01       Impact factor: 2.967

6.  Identification of novel prognostic factors focusing on clinical outcomes in patients with non-small cell lung cancer after stereotactic body radiotherapy.

Authors:  Hikari Sato; Fumiki Ito; Kazuki Hasegawa; Ryo Saga; Yoichiro Hosokawa; Mitsuki Tanaka; Masahiko Aoki
Journal:  Oncol Lett       Date:  2022-01-11       Impact factor: 2.967

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.